Biotech entity
Jazz Pharmaceuticals is most often covered alongside AACR Annual Meeting, which appears in 1 of these 2 stories. Across a 9-day span, the pace is roughly 1.6 stories per week. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window.
Last mentioned: Mar 18, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Jazz Pharmaceuticals is most often covered alongside AACR Annual Meeting, which appears in 1 of these 2 stories. Across a 9-day span, the pace is roughly 1.6 stories per week. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. The 6 average consequence score is below the beat benchmark of 6.1 in the same window. The clearest coverage concentration is clinical-trial: 1 of 2 stories, with the rest divided among 1 other category. We currently track 2 Biotech stories that mention Jazz Pharmaceuticals, published between March 10, 2026 and March 18, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 131 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Jazz Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Anticipated Regulatory Milestones
Potential for further regulatory filings based on ongoing Phase 3 data.
AACR Annual Meeting
Expected dates for the 2026 AACR meeting where Ziihera data will be showcased.
Presentation Announcement
Zymeworks announces multiple abstracts accepted for AACR 2026.
Zymeworks Inc. (ZYME) has announced multiple upcoming presentations for its lead asset, Ziihera (zanidatamab-hrii), at the 2026 AACR Annual Meeting. These presentations are expected to showcase the therapeutic's efficacy and safety across various HER2-expressing cancers, reinforcing its position in the competitive oncology landscape.
Emerging research indicates that specific non-psychoactive cannabis compounds, particularly THCV, may reverse Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). This breakthrough offers a potential pharmaceutical path for a condition that currently affects nearly 33% of the global adult population.
Jazz Pharmaceuticals is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
